Celecoxib Seems to Carry No Greater CV Risk Than Nonselective NSAIDs in Patients with Arthritis (FREE)

By Amy Orciari Herman Edited by Susan Sadoughi, MD, and Andr é Sofair, MD, MPH The COX-2 inhibitor celecoxib does not confer greater cardiovascular risk than nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with arthritis, according to an industry-supported, noninferiority trial. The findings were published on Sunday in the New Engl and Journal of Medicine …
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news